PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CONGESTIVE HEART FAILURE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 235 records · Page 13Linked to original sources

Cost-effective outpatient management of persons with heart failure.

Congestive heart failure remains one of the most prevalent and costly syndromes to treat throughout the world. In an era when cost-effective, quality, outcome-based care is a mandate, advanced practice nurse managed heart failure clinics propose a solution to this formidable problem. This paper examines a model of care based on self-monitoring utilized by an advanced practice nurse to effect the inter-related outcomes of readmission and cost of care.

Ambulatory Care↗

Large animal models of heart failure.

Congestive heart failure (HF) is a major focus of medical research. Its incidence has greatly increased in recent decades because of an aging population base and the increasingly successful treatment of other forms of chronic cardiac disease. Relevant large animal models of HF should reflect the complex interactions of cardiac dysfunction, neurohumoral dynamics and peripheral vascular abnormalities found in human HF. A number of large animal models have been developed, especially in dogs, sheep and swine, using naturally occurring HF, or single or combinations of interventions, as instruments to trigger the development of HF. Naturally occurring HF models are not commonly used because of ethical or perceived ethical grounds, however, King Charles Cavalier Spaniel and Yucatan Mini Pig models have been described. Tachycardia induced HF is the most commonly used HF model. Ventricular pacing at 220-240 bpm results in profound low output, biventricular, oedematous failure in two to three weeks. Lower pacing rates result in a more stable, sustainable, lesser degree of failure. Positive features of this model include 'acceptance', aetiological relevance to patient tachycardia induced HF, neurohumoral and functional profile similar to most human HF, relatively low cost simple preparation, ability to manipulate the degree of failure with pacing rate, reversibility, reliability and a large amount of published multi species data. Limitations to the use of the model are the rapid onset, the fact that reversibility is only relevant to the tachycardia induced patient HF, the absence of hypertrophy in failure, the diminished plasma atrial natriuretic peptide (ANP) levels, absence of ANP of ventricular origin, and the interference between rapid pacing and therapeutic interventions. Myocardial damage models of HF include those models induced by ischaemia, eg due to coronary occlusion (ligation or aneroid) or intracoronary microembolism, transmyocardial DC shock, toxic cardiomyopathy from adriamycin, doxorubicin or catecholamines. Overload models of HF may be induced by high pressure from aortic constriction, aortic regurgitation, renal artery constriction, pulmonary stenosis or aortocaval shunts, or by induction of mitral regurgitation from chordae or leaflet damage. No single, all-encompassing, large animal model of HF exists to date. Selection of the type of model to be used should be based primarily on the hypotheses to be tested and secondarily on the available resources and facilities.

Animals↗

Apoptosis and atrophy in rat slow skeletal muscles in chronic heart failure.

Congestive heart failure is characterized by a skeletal muscle myopathy with muscle bulk loss. The mechanisms responsible for these changes are not clear at present. We have investigated the role of apoptosis in the rat "slow" soleus muscle during the development of heart failure, which was induced by injection of monocrotaline (30 mg/kg). We looked at the time course of apoptosis by studying six animals at each of the following time points: 0, 17, 24, and 30 days. We found a decreased expression of the antiapoptotic protein Bcl-2, which was accompanied by a rise of proapoptotic caspase-3. Ubiquitin levels did not change. DNA nick-end labeling showed an increased number of apoptotic nuclei both in myofibers and interstitial cells when heart failure occurred. At variance with previous observations in the fast-twitch tibialis anterior muscle in the same animals, in which tumor necrosis factor-alpha (TNF-alpha) increased at the time that apoptosis occurred, the magnitude of apoptosis is lower in soleus muscle and there is no appearance of muscle atrophy. In soleus muscle, apoptosis is accompanied by activation of the caspase-3 system. There is no activation of the TNF-alpha- and ubiquitin-dependent protein waste. In conclusion, slow muscles are less prone to develop apoptosis than fast muscles. Muscle atrophy appears earlier in these latter ones.

Animals↗

Alterations in cardiac adrenergic terminal function and beta-adrenoceptor density in pacing-induced heart failure.

Congestive heart failure is associated with cardiac adrenergic nerve terminal changes and beta-adrenoceptor density downregulation. To study the temporal sequence of these changes, we performed studies in rabbits at 2, 4, and 8 wk of cardiac pacing (360 beats/min) and at 1, 2, and 4 wk after cessation of pacing. Rapid pacing produced left ventricular (LV) dysfunction and an increase in plasma norepinephrine (NE) in 1-2 wk. At week 2, NE uptake activity, NE uptake-1 density, and adenylyl cyclase responses to isoproterenol, 5'-guanylyl imidodiphosphate [Gpp(NH)p], and forskolin reduced. However, immunostained tyrosine hydroxylase profile, beta-adrenoceptor density, and NE histofluorescence did not reduce until 4-8 wk of pacing. After cessation of cardiac pacing, LV function normalized quickly, followed by return of tyrosine hydroxylase and NE profiles in 1 wk and adenylyl cyclase responses to agonists and NE uptake activity in 2 wk. Myocardial beta-adrenoceptor density returned to normal by 4 wk after cessation of pacing. Our results suggest that there is no permanent structural neuronal damage in the myocardium within the first 8 wk of rapid cardiac pacing. Abnormal myocardial NE reuptake mechanism may play an important pathophysiological role in heart failure.

Adenylyl Cyclases↗

Oxidative stress contributes to vascular endothelial dysfunction in heart failure.

Congestive heart failure (HF) is characterized by inadequate nitric oxide (NO) production in the vasculature. Because NO is degraded by oxygen radicals, we hypothesized that NO is degraded faster in HF from inadequate peripheral arterial antioxidant reserves. HF was induced in male Sprague-Dawley rats by left coronary artery ligation. Vascular endothelial function was evaluated by measuring the NO-mediated vasorelaxation response to acetylcholine (ACh; 10(-9)-10(-4) M) in excised aortas. This was repeated with the free radical generator pyrogallol (20 microM) and again with pyrogallol and superoxide dismutase (SOD; 60 U/ml). Aortic and myocardial SOD activity was also determined. ACh-induced vasorelaxation was reduced in HF (n = 9) compared with normal control rats (n = 11; P < 0.001). Pyrogallol further reduced vasorelaxation in HF: 74 +/- 11% at 10(-4) M ACh versus 58 +/- 10% in normal control rats (P < 0.004). There was a trend (P = 0.06) toward reduced SOD activity in HF aortas. In conclusion, altered NO-dependent vasorelaxation in HF is in part due to excessive degradation of NO and is likely related to reduced vascular SOD activity.

Animals↗

Coronary beta-adrenoceptor function is modified by the endothelium in heart failure.

Congestive heart failure is associated with abnormalities in myocardial beta-adrenoceptor function. The extent of vascular beta-adrenoceptor alterations at heart failure, however, is unknown. Accordingly, we examined beta-adrenoceptor-mediated relaxations in both circumflex (CRX) and left anterior descending (LAD) coronary arteries with and without endothelium from dogs in early and end-stage heart failure induced by rapid ventricular pacing (1 and 4 weeks pacing at 250 beats x min-1, respectively). At early heart failure, (1) CRX with endothelium were more sensitive to isoproterenol than CRX without endothelium (EC50: 1.1 x 10(-8) vs. 1.6 x 10(-7) M, p<0.05); and (2) in response to salbutamol, CRX with endothelium had a lower maximum relaxation response than CRX without endothelium (56.6 vs. 75.9%, p<0.05). At end-stage heart failure, (1) endothelium-intact CRX and LAD showed a significant decrease in sensitivity to isoproterenol compared to control (CRX-EC50: end-stage heart failure: 1.1 x 10(-7) vs. control: 1.8 x 10(-8)M,p<0.05; and LAD-EC50: end-stage heart failure: 8.8 x 10(-7) M vs. control: 8.3 x 10(-8) M, p<0.05); (2) LAD with endothelium showed greater maximum relaxation to salbutamol than LAD without endothelium (100.8 vs. 76.5%, p<0.05); and (3) CRX were significantly more sensitive to isoproterenol than LAD. These data suggest that coronary vascular tone via beta-adrenoceptor stimulation is coronary artery-dependent, and modulated not only by the heart failure state, but also by the presence of a functional endothelium.

Adrenergic beta-Agonists↗

Which drug for what patient with heart failure, and when?

Congestive heart failure is emerging as an important public health problem because of its frequency and high mortality. Over the past decade, a number of clinical trials have been launched in a systematic attempt to determine an optimal therapeutic strategy for the treatment of heart failure. There appears to be a trend to begin treatment with both a diuretic and a vasodilator regimen in patients with symptomatic left ventricular dysfunction. Converting enzyme inhibitors have been shown to clearly benefit patients with class IV heart failure. The role of digitalis, other inotropic agents, beta-blockers, partial beta-agonists and antiarrhythmic agents is still evolving, but several clinical trials of these agents have been recently launched or are in the planning stages. Patients with symptomless left ventricular dysfunction are at risk to develop heart failure. One attractive hypothesis being tested is that preventive therapy with converting enzyme inhibitors may prevent progressive cardiac dilatation and thereby improve survival in this important reservoir of patients. Until the results of these numerous clinical trials are published, physicians should reserve judgement regarding the undefined efficacy of various investigational agents used in the treatment of heart failure and use their experience and judgement when planning a therapeutic strategy for their individual patients.

Adrenergic beta-Antagonists↗

Alterations of signal transduction system in heart failure.

Congestive heart failure (CHF) patients share several similar features, such as reduced cardiac contractility and neurohumoral activation to compensate the impaired cardiac function. In CHF patients, the cardiac renin-angitensin (RA) system, receptors, GTP-binding proteins, and their effector molecules are inevitably exposed to chronically elevated neurohumoral stimulation. A widely recognized concept is that a chronic increase in such stimulation can desensitize target cell receptors and the post-receptor signal transducing pathway. Recently, reports of several studies have indicated that the inhibitory GTP-binding protein (Gi) can be increased in CHF patients and animal models. Although direct evidence for a change in catalytic protein of adenylyl cyclase has not been found, limited information has suggested a reduced catalytic activity in terminally failing hearts. In this paper, we have assessed the changes in beta AR, GTP-binding protein, catalytic protein and beta ARK. We also examined angiotensinogen mRNA expression in failing heart. It was detected not only in the liver, but also in both the atrial and ventricular heart tissues, suggesting that angiotensinogen is synthesized in the human heart. Immunohistochemical studies revealed a stronger reaction in the endocardial layer of the human left ventricle than in the epicardial layer, and intense immunoreactivity in the conduction system and right atrium. Our experiments revealed a widespread immunopositive reaction for angiotensinogen in the left ventricle of diseased hearts. In the non-diseased heart, ACE and AT1 receptor RNA are present in ventricular muscles. Renin and Ao mRNA could not be detected in the subendocardium of non-diseased left ventricle, but both were present in the left ventricle of diseased hearts. These data indicate that the cardiac RA system plays an important role in the deterioration of cardiac function.

Angiotensinogen↗

Use of the MicroMed DeBakey VAD for the treatment of end-stage heart failure.

Congestive heart failure poses a serious health risk to millions of Americans. Medical therapy for advanced stages of this condition has offered a minimal benefit and surgical treatment through transplantation is limited by the donor organ shortage. Although left ventricular assist devices may represent the future of therapy for this disease, the first generation of these pumps are limited by a number of factors that restrict their use to only the sickest of patients. The development and clinical use of the MicroMed DeBakey VAD represents a paradigm shift in the field of heart disease, supporting the notion that mechanical assistance can be achieved with continuous flow pumps. Axial flow devices, such as the DeBakey VAD, may open new doors for smaller patients and children, as well as improve the current standard of care for adults who require long-term circulatory support.

Chronic Disease↗

Calcium sensitising agents in heart failure.

Congestive heart failure (CHF) is a common cardiovascular disorder that is characterised, in part, by a decreased cardiac output reserve. Accordingly, there is ongoing interest in the role of positive inotropic agents (e.g. adrenergic agonists and phosphodiesterase type III inhibitors, which mediate their cardiovascular effects via a cyclic adenosine monophosphate-dependent mechanism) in the treatment of CHF. However, enthusiasm for positive inotropic therapy in CHF has been dampened by the results of clinical trials, which have shown that these drugs are associated with an increased risk of mortality. Calcium sensitising agents are a heterogeneous group of positive inotropic agents that mediate their cardiovascular actions (at least in part) by increasing the sensitivity of the contractile elements to calcium. Increased sensitivity to calcium may be related to changes in calcium binding to troponin C, or to direct effects on the actin-myosin complex. In addition, the inhibition of phosphodiesterase type III may contribute to the positive inotropic action of calcium sensitising agents. Five agents with calcium sensitising properties (pimobendan, levosimendan, MCI-154, EMD-53998 and CGP-48506) have been studied as possible therapies for CHF. All of these agents have demonstrated a positive inotropic action in isolated cardiac tissue and in animal models of CHF. In clinical trials, pimobendan, the most extensively studied of these drugs, was well tolerated and was associated with improved exercise tolerance during the first 6 months of therapy; however, it was also associated with a nonsignificant trend towards increased mortality. Because many of the calcium sensitising agents also inhibit phosphodiesterase type III activity, the long term safety of these agents is uncertain. Large-scale survival trials are required to determine the long term safety and efficacy of these agents before their role in the treatment of CHF can be defined.

Aged↗

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.

Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like peptide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function. The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function. There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function. It is concluded that GLP-1 deserves further evaluation in such patients.

Blood Glucose↗

[The difficulties of translating into daily clinical practice the favorable results of clinical trials in chronic heart failure].

Congestive heart failure is a growing public health problem and continues to be characterized by a poor prognosis. Its prevalence may be estimated at 0.4-2% of the general population with an incidence varying from 1-10% in elderly patients. This may be in part explained by the progressive aging of the population and the more effective therapeutic strategies for coronary heart disease and hypertension: since they increase the life-expectancy of patients, they favor the onset of this clinical syndrome at a more advanced age. The number of hospital admissions has also increased; mortality is 50% within 4 years of diagnosis, although patients with very severe cardiac decompensation die within 1 year. Despite the fact that with the use of the most advanced molecules created by pharmacological research (ACE inhibitors, beta-blockers, angiotensin-II-receptor antagonists) a significant reduction in morbidity and mortality as well as clear improvement of symptoms and quality of life have been obtained in diverse clinical trials, there is still no certain evidence that in the general population, mortality due to chronic heart disease has been reduced. In our opinion, several factors explain the gap between the favorable results of clinical trials and the lack of significant reduction in morbidity and mortality in clinical practice: A) the selection criteria utilized in clinical studies exclude, for the most part, patients present in general population; B) the average age of the patients included (60 years) is not representative of the overall population; C) patients with associated co-morbidity are generally excluded; D) the number of women enrolled in the trials is quite low; E) compliance is certainly better in the trials than in clinical practice; F) higher drug dosages are used in the trials than in clinical practice. To intervene in these areas and thus make the positive results obtained in the trials available to the general population is, in our opinion, the principal challenge of the future. For this task, the close collaboration and commitment of the internist, the geriatrist, the cardiologist and the family doctors is necessary so that the results reported in clinical trials may be translated into general medical practice.

Aged↗

[Rational diagnosis of chronic heart failure].

Congestive heart failure is associated with a high mortality and morbidity. The aetiology of heart failure and the presence of exacerbating factors should be carefully assessed in all cases. The extent to which the cause of heart failure should be pursued by further investigations will depend on the resources available and the likelihood that a precise diagnosis will influence treatment. The clinical suspicion of heart failure should be confirmed by more objective tests, particularly aimed at assessing cardiac function. To achieve this goal a variety of non-invasive and invasive tests are available. For follow-up studies echocardiography and to a lesser extent chest x-ray may be helpful. It is expected that measurement of plasma concentration of natriuretic peptides may add important information to the diagnostic process of heart failure and will identify those patients at greatest risk for serious cardiovascular events. In the future, the development of new techniques in non-invasive diagnostic tests such as contrast echocardiography, computer tomography and cardiac magnetic resonance imaging will extend the diagnostic spectrum of heart failure.

Chronic Disease↗

[Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure].

Congestive heart failure is a leading cause of cardiovascular morbidity and mortality, and is the main cause of hospitalization among patients older than 65 years. Moreover, its prevalence is expected to reach nearly epidemic proportions, so that the need for new treatments is clear. In this article we review current and future strategies for the treatment of systolic heart failure that are based on a better understanding of the pathophysiology of this disorder and on the results of controlled clinical trials of different treatments. Drugs under development (phase II and III clinical trials) have been classified into four main groups: neurohumoral antagonists, inotropic agents, modulators of myocardial remodeling, and future approaches to treatment such as gene therapy and anti-apoptotic drugs. We also discuss new strategies for the treatment of diastolic heart failure.

Cardiotonic Agents↗

Baroreceptor reflex in heart failure.

Congestive heart failure is a syndrome that is usually initiated by a reduction in pump function of the heart, i.e. a decrease in cardiac output. Initially, a reduction in cardiac output leads to unloading of baroreceptor reflex that, in turn, increases heart rate through vago-sympathetic mechanisms and total peripheral resistance via an increase in sympathetic outflow to vascular beds. In this review we are thinking on how baroreceptor reflex plays a role in the abnormal control of the circulation in heart failure. This review and our recent studies suggest that: (1) baroreceptor reflex is blunted in heart failure; (2) central angiotensin II and reactive oxygen species play an important role in blunted baroreceptor reflex; (3) cardiac sympathetic afferent stimulation and chemoreceptor reflex inhibit baroreceptor reflex; and (4) exercise training normalizes abnormal reflexes in the heart failure state.

Angiotensin II↗

[Cardiac resynchronization therapy in refractory heart failure].

Congestive heart failure remains associated with substantial morbidity and mortality. A common finding in advanced heart failure is abnormal electrical activation of the ventricles or electrical ventricular dyssynchrony. In the early 90s, standard dual-chamber pacing with short AV delay was proposed as a supplementary treatment of drug-resistant heart failure. Initial results were encouraging but were never confirmed. These studies however made it possible to select a population of potentially responsive patients, especially those with a prolonged PR interval reflecting major atrioventricular asynchrony in the left heart. That relative failure of standard dual-chamber pacing could be linked to the fact that by capturing the ventricle from the right apex, it increases, or at least it cannot correct the marked asynchrony of activation, contraction and relaxation, which characterizes a number of patients with chronic left ventricular dysfunction. Such is the case in particular in patients with important QRS enlargement linked to major intraventricular conduction delay. Biventricular pacing, which simultaneously activates both ventricles, may contribute to correcting the asynchrony and thus improve cardiac performance.

Cardiac Pacing, Artificial↗

[Levosimendan: a new strategy in the treatment of heart failure].

Congestive heart failure is a long standing health issue. Traditionally, heart failure has been treated with a wide array of drugs such as diuretics, digitalis, catecholamine and non catecholamine inotropics, although treatment with these drugs bears adverse effects, such as the generation of arrhythmia and even death. A new class of drugs has recently exerted a positive impact on the treatment of patients with heart failure; these are the calcium sensitizers that enhance myocardial contractility without increasing cytosolic calcium. Levosimendan is a calcium sensitizer that, besides increasing contractility, has a vasodilating effect due to the activation of K(ATP) channels, being both mechanisms responsible for an advantageous therapeutic option. Different studies have proven the efficiency and safety profile of the drug on various scenarios and populations; thereby considering levosimendan a real and safe alternative treatment for patients with acute or chronic ventricular failure that need intravenous pharmacological support.

Heart Failure↗

[Permanent cardiostimulation in the treatment of heart failure].

Congestive heart failure is a major health problem reaching epidemic proportions in the industrialized world. Despite significant advances in medical therapy, prognosis still remains dim. Cardiac resynchronization therapy is a novel therapeutic approach in management of heart failure patients. Its goal is the restoration of an impaired cardiac synchrony, which can be found in high number of heart failure patients. Cardiac dyssynchrony is characterized by presence of intra and interventricular conduction delays. Cardiac synchrony can be regained by biventricular stimulation. The procedure consists of a special lead being inserted via coronary sinus to a suitable branch of cardiac veins of the left ventricle in addition to a lead in the right ventricle cavity and right atrium. Several clinical trials have demonstrated that cardiac resynchronization therapy improves functional status and quality of life in majority of patients, as well as renders a favourable impact on prognosis.

Cardiac Pacing, Artificial↗